A common women’s health condition formerly known as Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to give a clearer picture of the condition’s wide effects on the body. Medical experts and patient groups worldwide agreed on the new name after years of review and discussion.

The old name focused too much on cysts in the ovaries, which many women with the condition do not actually have. The new name, PMOS, better shows how the condition affects hormones, metabolism, reproductive health, mental well-being, skin, and weight. It impacts about one in eight women around the world, causing issues like irregular periods, excess hair growth, acne, and higher risks of diabetes and heart problems.

Professor Helena Teede of Monash University led the global effort. She explained that the previous name caused confusion, delayed diagnoses, and poor treatment for many women.

Over 50 professional and patient organisations took part in the process, which included surveys from more than 22,000 people and input from women living with the condition.

The renaming is expected to improve awareness among doctors and patients. It will also help reduce stigma and encourage better long-term care. A three-year transition period has started, with full change planned for international medical guidelines in 2028.

This update marks an important step in women’s healthcare. By using a more accurate name, experts hope more women will get timely diagnosis and proper support. The change is seen as a major achievement that could lead to improved research and treatment for millions affected by PMOS.